Doryx Mpc is a drug owned by Mayne Pharma International Pty Ltd. It is protected by 5 US drug patents filed in 2016. Out of these, 4 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 23, 2034. Details of Doryx Mpc's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9446057 | Controlled release doxycycline |
Dec, 2034
(10 years from now) | Active |
| US9511031 | Controlled release doxycycline |
Oct, 2034
(9 years from now) | Active |
| US9295652 | Controlled release doxycycline |
Oct, 2034
(9 years from now) | Active |
| US8715724 | Tabletting process |
Feb, 2028
(3 years from now) | Active |
| US6958161 | Modified release coated drug preparation |
Dec, 2022
(1 year, 11 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Doryx Mpc's patents.
Latest Legal Activities on Doryx Mpc's Patents
Given below is the list of recent legal activities going on the following patents of Doryx Mpc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jun, 2024 | US9511031 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2020 | US9511031 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Feb, 2020 | US9446057 |
| Email Notification Critical | 10 Jun, 2019 | US9511031 |
| Email Notification Critical | 10 Jun, 2019 | US9446057 |
| Change in Power of Attorney (May Include Associate POA) Critical | 10 Jun, 2019 | US9511031 |
| Change in Power of Attorney (May Include Associate POA) Critical | 10 Jun, 2019 | US9446057 |
| Correspondence Address Change Critical | 07 Jun, 2019 | US9511031 |
| Correspondence Address Change Critical | 07 Jun, 2019 | US9446057 |
| Miscellaneous Incoming Letter | 11 Jun, 2018 | US9446057 |
US patents provide insights into the exclusivity only within the United States, but Doryx Mpc is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Doryx Mpc's family patents as well as insights into ongoing legal events on those patents.
Doryx Mpc's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Doryx Mpc's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 23, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Doryx Mpc Generic API suppliers:
Doxycycline Hyclate is the generic name for the brand Doryx Mpc. 59 different companies have already filed for the generic of Doryx Mpc, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Doryx Mpc's generic
How can I launch a generic of Doryx Mpc before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Doryx Mpc's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Doryx Mpc's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Doryx Mpc -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 75 mg and 100 mg | 1 | 28 Dec, 2010 | 15 Dec, 2022 | Eligible | |
| 150 mg | 19 Dec, 2008 | 1 | 15 Dec, 2022 | Extinguished | |
| 200 mg | 19 May, 2014 | 1 | 19 May, 2016 | 15 Dec, 2022 | Eligible |
| 80 mg | 01 Jul, 2015 | 1 | 29 Apr, 2016 | 15 Dec, 2022 | Extinguished Eligible |
| 50 mg | 05 Nov, 2015 | 1 | 23 May, 2016 | 03 Feb, 2028 | Eligible |
| 60 mg and 120 mg | 28 Sep, 2017 | 1 | 23 Dec, 2034 | Extinguished |
Alternative Brands for Doryx Mpc
Doryx Mpc which is used for treating or preventing infections caused by susceptible bacteria., has several other brand drugs in the same treatment category and using the same active ingredient (Doxycycline Hyclate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Mayne Pharma |
| |||
Apart from brand drugs containing the same ingredient, some generics have also been filed for Doxycycline Hyclate, Doryx Mpc's active ingredient. Check the complete list of approved generic manufacturers for Doryx Mpc
About Doryx Mpc
Doryx Mpc is a drug owned by Mayne Pharma International Pty Ltd. It is used for treating or preventing infections caused by susceptible bacteria. Doryx Mpc uses Doxycycline Hyclate as an active ingredient. Doryx Mpc was launched by Mayne Pharma in 2014.
Approval Date:
Doryx Mpc was approved by FDA for market use on 19 December, 2014.
Active Ingredient:
Doryx Mpc uses Doxycycline Hyclate as the active ingredient. Check out other Drugs and Companies using Doxycycline Hyclate ingredient
Treatment:
Doryx Mpc is used for treating or preventing infections caused by susceptible bacteria.
Dosage:
Doryx Mpc is available in tablet, delayed release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, DELAYED RELEASE | Discontinued | ORAL |
| EQ 60MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, DELAYED RELEASE | Prescription | ORAL |